Charles River Laboratories International Inc.

CRL | NYSE

Price Alert Chart Builder DCF Calculator

$359.69

-$16.41 (-4.36%)

At close: Oct 30, 2026, 3:59 PM ET

$361.50

+$1.81 (+0.50%)

Pre-market: Nov 2, 2026, 5:08 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-4.36%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

32.2

-0.1 pts

Fundamentals Weak

Market Sentiment Bullish

Moat Narrow

Sector Rank #733/1028 (Top 71%)

Full Analysis

Key Statistics

Market Data

Market Cap $17.33B

1D Range

352.20 374.44

52W Range

149.93 374.44

Valuation (TTM)

PE -74.16

PB 6.10

EV/EBITDA 91.45

Valuation (NTM)

Forward PE 27.98

Forward PEG -6.69

Price Target $308.36

Cash Flow

FCF Yield 2.1%

SBC Adj. FCF Yield 1.8%

SBC Impact -17.6%

Margins

Gross Margin 32.2%

Operating Margin 12.3%

FCF Margin 9.3%

Growth (CAGR)

Revenue 3Y | 5Y -1.4% | 4.1%

Dil EPS 3Y | 5Y -912.4% | -93.2%

FCF 3Y | 5Y 8.6% | -5.2%

Returns

ROA -3.2%

ROE -7.7%

ROIC 7.7%

Financial Health

Net Debt

$2.43B

Current Ratio 1.35

Interest Coverage 4.65

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core...

Sector Healthcare

Industry Medical - Diagnostics & Research

Employees 19,000

IPO Date Jun 23, 2000

Website www.criver.com

Fiscal Year January - December

Full Company Profile

Latest News

4 days ago · zacks.com

Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 days ago · businesswire.com

Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announced a collaboration with the U.S. FDA and Labcorp to develop screening tools to quantify and rank the abuse potential of new drugs.

24 days ago · businesswire.com

Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call.

26 days ago · zacks.com

Charles River Gains 75.8% in a Year: What's Driving the Rally?

CRL shares have surged 75.8% in a year as RMS trends improve, AI-enabled testing expands and cash flow supports buybacks and investment.

27 days ago · businesswire.com

Charles River and Autolomous Partner to Transform Laboratory Execution Systems

WILMINGTON, Mass. & LONDON--(BUSINESS WIRE)---- $CRL #DrugDiscover--Charles River Laboratories International, Inc. (NYSE: CRL) and Autolomous today announced the launch of Apollo Orchestrate™, a new capability within Charles River's Apollo® platform that connects and digitizes laboratory execution, built on Autolomous's autoloMATE® digital Laboratory Execution System (LES). The launch demonstrates continued progress on Charles River's strategic commitment to modernize and digitize laboratory workflows. Apollo® Orches.

1 month ago · marketbeat.com

Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan

Charles River Laboratories International NYSE: CRL outlined a strategy to accelerate growth, expand margins and modernize its operations during its 2026 Investor Day, setting financial targets through 2030 that include 5% to 7% organic revenue growth, an approximately 24% non-GAAP operating margin and low-double-digit non-GAAP earnings-per-share growth.

1 month ago · seekingalpha.com

Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript

1 month ago · businesswire.com

Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day.

2 months ago · businesswire.com

Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) has introduced rapid cell banking programs designed to significantly accelerate release timelines, enabling biopharmaceutical and advanced therapy developers to reach critical milestones faster and bring innovative treatments to patients sooner. By combining rapid cell bank and release packages with advanced characterization using Next-Generation Sequencing (NGS), Charles River delivers a comprehensiv.